0001209191-20-021178.txt : 20200325 0001209191-20-021178.hdr.sgml : 20200325 20200325184702 ACCESSION NUMBER: 0001209191-20-021178 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200323 FILED AS OF DATE: 20200325 DATE AS OF CHANGE: 20200325 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cui Jingrong Jean CENTRAL INDEX KEY: 0001772259 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38871 FILM NUMBER: 20743502 MAIL ADDRESS: STREET 1: C/O TURNING POINT THERAPEUTICS, INC. STREET 2: 10628 SCIENCE CENTER DR., STE. 225 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Turning Point Therapeutics, Inc. CENTRAL INDEX KEY: 0001595893 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463826166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-926-5251 MAIL ADDRESS: STREET 1: 10628 SCIENCE CENTER DRIVE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: TP Therapeutics, Inc. DATE OF NAME CHANGE: 20181018 FORMER COMPANY: FORMER CONFORMED NAME: TP Therapeutics, INC DATE OF NAME CHANGE: 20140106 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-03-23 0 0001595893 Turning Point Therapeutics, Inc. TPTX 0001772259 Cui Jingrong Jean C/O TURNING POINT THERAPEUTICS, INC. 10628 SCIENCE CENTER DRIVE, STE. 200 SAN DIEGO CA 92121 1 0 0 0 Common Stock 1001298 D Common Stock 300000 I By The Jean Cui 2020 GRAT Common Stock 2020-03-23 4 S 0 900 36.52 D 824483 I By spouse Common Stock 2020-03-23 4 S 0 1900 37.88 D 822583 I By spouse Common Stock 2020-03-23 4 S 0 3000 38.77 D 819583 I By spouse Common Stock 2020-03-23 4 S 0 1200 39.63 D 818383 I By spouse Common Stock 2020-03-24 4 S 0 1300 40.75 D 817083 I By spouse Common Stock 2020-03-24 4 S 0 3200 41.73 D 813883 I By spouse Common Stock 2020-03-24 4 S 0 2100 42.72 D 811783 I By spouse Common Stock 2020-03-24 4 S 0 400 43.58 D 811383 I By spouse Common Stock 2020-03-25 4 S 0 2100 44.56 D 809283 I By spouse Common Stock 2020-03-25 4 S 0 13292 45.35 D 795991 I By spouse Common Stock 2020-03-25 4 S 0 2200 46.50 D 793791 I By spouse Common Stock 2020-03-25 4 S 0 200 47.11 D 793591 I By spouse Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li. The weighted average sale price for the transaction reported was $36.52, and the range of prices were between $36.225 and $36.70. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $37.88, and the range of prices were between $37.35 and $38.29. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $38.77, and the range of prices were between $38.37 and $39.235. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $39.63, and the range of prices were between $39.38 and $39.94. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $40.75, and the range of prices were between $40.30 and $41.280. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $41.73, and the range of prices were between $41.30 and $42.240. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $42.72, and the range of prices were between $42.30 and $43.19. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $43.58, and the range of prices were between $43.345 and $43.88. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $44.56, and the range of prices were between $43.97 and $44.95. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $45.35, and the range of prices were between $44.97 and $45.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $46.50, and the range of prices were between $46.09 and $47.005. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $47.11, and the range of prices were between $47.105 and $47.11. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. /s/ Annette North, Attorney-in-Fact 2020-03-25